You are here: Industry Insights > Lineage Cell Therapeutics

News List

Lineage Cell Therapeutics to apply allogeneic dendritic cell therapy programme to Covid-19 vaccine d pharmaceutical-business-review
May 08, 2020
Lineage Cell Therapeutics, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
Advanced BioMatrix Acquires HyStem from Lineage Cell Therapeutics americanpharmaceuticalreview
January 15, 2020
Advanced BioMatrix has acquired the HyStem® line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan. HyStem kits are based on thiolated hyaluronic acid technology.
Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets firstwordpharma
December 25, 2019
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilit
Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets firstwordpharma
December 24, 2019
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced that it has entered into license agreements with three separate companies,